Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: Mirror Image who wrote (1887)	4/28/2016 8:41:54 AM
From: eico20	Respond to of 2026

very good analysis MI, a public statement regarding a Sandoz relaunch in Germany would be significant news , imo

To: Mirror Image who wrote (1887)	4/29/2016 2:18:03 PM
From: Strong Long	Read Replies (1) \| Respond to of 2026

MI great analyses. Thanks for your efforts to breakdown all that information. Great summary of the delisting pathway...provides a lot of clarity on the matter. To the group collectively, some thoughts about the Ferring Takeda deal. Four days ago, Apricus provided a corporate update on their website. There was no mention that Takeda had been replaced by Ferring to market in the UK. In fact, they still included Takeda in the corporate update as being one of their marketing partners...not a fan of the lack of transparency. I understand the notion that it's better to get somebody in place to market Vitaros if another company is not doing it to our company's satisfaction, but giving up milestone payments (even if on paper) and taking lower tired royalties, does not feel like winning to me. Sure if no volume in sales was being generated, going another direction could in theory be the better move, but our first to market Vitaros partner is saying no thanks. I have always had one major concern with Vitaros, and that is this question, "is it effective?" Logic seems to dictate that if it is, it should fly off the shelves, if it's not, then it will start to present itself... I've seen the articles related to it's efficacy and something is not stacking up here... Either way, it doesn't make sense that I get out of APRI now...I can only hold on and hope that our management executes and that are product works.